Search
News & Events
‘Mama’ deb’s dedication to saving children in Papua New GuineaChildren living in Papua New Guinea have good reason to call Clinical Associate Professor Deborah Lehmann ‘Mama Deb’.
News & Events
Sharing the power of data at TEDx PerthDr Hannah Moore was one of WA’s brightest minds chosen to speak at TEDX Perth in November last year, presenting her insights into the power of data in fighting infectious diseases to a sold-out crowd at the Perth Concert Hall.
News & Events
First week of school visits mark official launch of the SToP TrialThe The Kids Skin Health team has a busy six weeks ahead - visiting nine communities throughout the Kimberley region of WA as part of the first school surveillance activities for the SToP Trial.
News & Events
Ear health partnership brings brighter future for Aboriginal kidsA new partnership between The Kids Research Institute Australia, Dr George Sim and St John of God Murdoch Hospital will offer essential surgery at no cost for a group of Aboriginal children suffering severe ear infections.
News & Events
Meningococcal vaccine provides extra protection for bubsIn 2017, a steep rise in cases of meningococcal disease caused by the W strain sparked a wave of concern for parents in Western Australia.
News & Events
The Kids researcher awarded Research Translation Projects grantA new research project aims to demonstrate how influenza vaccination in children could be a highly cost-effective health care intervention in Australia.
Pneumococcal – a bacterial infection that can cause pneumonia and meningitis – is responsible for 1000s of hospital admissions in Australia each year, many of them children.
Research
Immunogenicity, Reactogenicity, and Safety of a Pentavalent Meningococcal ABCWY Vaccine in Adolescents and Young Adults who had Previously Received a Meningococcal ACWY VaccineA MenABCWY vaccine containing 4CMenB and MenACWY-CRM vaccine components has been developed to protect against the 5 meningococcal serogroups that cause most invasive disease cases.
Research
Short term safety profile of respiratory syncytial virus vaccine in adults aged ≥ 60 years in AustraliaAustralia's active vaccine safety surveillance system AusVaxSafety monitors a number of vaccines, including Arexvy, by reporting on solicited adverse events following immunisation (AEFI) through an online survey sent to vaccinees 3 days post-vaccination as previously described.3 Here we report on survey responses from adults aged ≥60 years receiving Arexvy at primary healthcare practices or pharmacies, who responded to the survey by day 7 post-vaccination.
Research
FeBRILe3: Risk-Stratification and Diagnosis of Serious Bacterial Infections in Febrile Infants Less Than 3 Months OldEvidence-based recommendations exist for early discharge (before 48 h) of young infants with fever without source (FWS) at low risk of serious bacterial infections (SBIs). However, concerns regarding the applicability of international data to local contexts may hinder implementation. We aimed to describe the local epidemiology of FWS and evaluate a newly implemented risk-stratification guideline to support practice change.